HK1213636A1 - 識別病患對投予 受體調節劑之反應 - Google Patents

識別病患對投予 受體調節劑之反應

Info

Publication number
HK1213636A1
HK1213636A1 HK16101571.7A HK16101571A HK1213636A1 HK 1213636 A1 HK1213636 A1 HK 1213636A1 HK 16101571 A HK16101571 A HK 16101571A HK 1213636 A1 HK1213636 A1 HK 1213636A1
Authority
HK
Hong Kong
Prior art keywords
receptor modulator
patient response
identifying patient
modulator administration
administration
Prior art date
Application number
HK16101571.7A
Other languages
English (en)
Inventor
Hubert Borell
Anne Gardin
Yi Jin
Eric Legangneux
Mike Ufer
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48142792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1213636(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1213636A1 publication Critical patent/HK1213636A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Ecology (AREA)
HK16101571.7A 2013-04-04 2016-02-12 識別病患對投予 受體調節劑之反應 HK1213636A1 (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361808406P 2013-04-04 2013-04-04
US201361811321P 2013-04-12 2013-04-12
US201361813380P 2013-04-18 2013-04-18
PCT/EP2013/058226 WO2014161606A1 (en) 2013-04-04 2013-04-19 Identifying patient response to s1p receptor modulator administration

Publications (1)

Publication Number Publication Date
HK1213636A1 true HK1213636A1 (zh) 2016-07-08

Family

ID=48142792

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16101571.7A HK1213636A1 (zh) 2013-04-04 2016-02-12 識別病患對投予 受體調節劑之反應

Country Status (19)

Country Link
US (5) US20160046573A1 (zh)
EP (4) EP4191245A3 (zh)
JP (3) JP6240746B2 (zh)
KR (1) KR102166228B1 (zh)
AR (1) AR090929A1 (zh)
AU (3) AU2013385181A1 (zh)
BR (1) BR112015020140A8 (zh)
CA (2) CA3149287A1 (zh)
CL (1) CL2015002933A1 (zh)
ES (1) ES2941941T3 (zh)
HK (1) HK1213636A1 (zh)
IL (2) IL252497B (zh)
MX (1) MX2015014014A (zh)
PH (1) PH12015502291A1 (zh)
RU (1) RU2015141151A (zh)
SG (2) SG11201506493VA (zh)
TN (1) TN2015000333A1 (zh)
TW (1) TW201438716A (zh)
WO (1) WO2014161606A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX357304B (es) 2011-01-07 2018-07-04 Novartis Ag Formulaciones inmunosupresoras.
MX2015014014A (es) * 2013-04-04 2016-02-10 Novartis Ag Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p.
CA2964315A1 (en) * 2014-10-16 2016-04-21 Novartis Ag Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
CA2973540A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
WO2017120124A1 (en) 2016-01-04 2017-07-13 Auspex Pharmaceuticals, Inc. Azetidine modulators of the sphingosine 1-phosphate receptor
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en) 2017-03-09 2023-04-18 Novartis Ag Solid forms comprising an oxime ether compound, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150088A (en) * 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
IL294658A (en) * 2008-12-22 2022-09-01 Novartis Ag Dosage regimen of an s1p receptor agonist
US20120264719A1 (en) * 2009-09-29 2012-10-18 Craig Boulton Dosage regimen of an s1p receptor modulator
MX2015014014A (es) * 2013-04-04 2016-02-10 Novartis Ag Identificacion de la respuesta del paciente a la administracion de un modulador del receptor s1p.

Also Published As

Publication number Publication date
US20190135744A1 (en) 2019-05-09
JP2018076316A (ja) 2018-05-17
CL2015002933A1 (es) 2016-07-29
JP2019104737A (ja) 2019-06-27
PH12015502291A1 (en) 2016-02-15
AU2017202470A1 (en) 2017-05-04
EP3647783A2 (en) 2020-05-06
JP6240746B2 (ja) 2017-11-29
EP2981819A1 (en) 2016-02-10
ES2941941T3 (es) 2023-05-26
AU2019202036A1 (en) 2019-04-18
RU2015141151A (ru) 2017-05-10
SG11201506493VA (en) 2015-10-29
TW201438716A (zh) 2014-10-16
KR102166228B1 (ko) 2020-10-16
EP4191245A2 (en) 2023-06-07
IL284999A (en) 2021-08-31
SG10201707826RA (en) 2017-10-30
AU2019202036B2 (en) 2021-07-08
AU2013385181A1 (en) 2015-08-27
US20240270688A1 (en) 2024-08-15
US20160046573A1 (en) 2016-02-18
EP3647783B1 (en) 2022-12-21
WO2014161606A9 (en) 2015-11-19
EP3647783A3 (en) 2020-07-15
EP3199947A2 (en) 2017-08-02
AR090929A1 (es) 2014-12-17
BR112015020140A8 (pt) 2019-11-19
KR20150139510A (ko) 2015-12-11
CA3149287A1 (en) 2014-10-09
JP2016518350A (ja) 2016-06-23
BR112015020140A2 (pt) 2017-07-18
EP3199947A3 (en) 2017-09-13
IL252497B (en) 2021-08-31
WO2014161606A1 (en) 2014-10-09
RU2018144563A (ru) 2019-02-01
US20170320820A1 (en) 2017-11-09
MX2015014014A (es) 2016-02-10
TN2015000333A1 (en) 2017-01-03
JP6934481B2 (ja) 2021-09-15
US20210147354A1 (en) 2021-05-20
CA2900844C (en) 2022-05-03
EP4191245A3 (en) 2023-07-12
IL252497A0 (en) 2017-07-31
CA2900844A1 (en) 2014-10-09

Similar Documents

Publication Publication Date Title
IL279408B (en) An infusion system to prevent the wrong referral of a large number of drugs
IL245349A0 (en) Patient control system
HK1221672A1 (zh) 鼻腔給藥
IL284999A (en) Identification of the patient's response to administration of a S1P receptor modulator
AU357213S (en) Patient interface
EP2922514A4 (en) PATIENT BI-RADIAL INTERFACE
AU353287S (en) Patient interface
AU353289S (en) Patient interface
DK3639872T3 (da) Lægemiddeladministrationsanordning
IL268718B (en) Opioid receptor modulator dosage formulation
PT2981325T (pt) Dispositivo de ligação para sistema de administração de fluidos de tratamento médico
EP2902052A4 (en) MEDICAL LIQUID ADMINISTRATION DEVICE
EP2968179A4 (en) RETARD-PRESENTATIONS
SI3046537T1 (sl) Farmacevtski pripravek ogljikovih hidratov za terapevtsko uporabo
GB201313356D0 (en) Therapeutic Intervention
DK3071267T3 (da) Lægemiddeladministrationsanordning med ensrettet kobling
UA28330S (uk) Капсула для лікарського засобу
PL2840757T3 (pl) Indywidualne centralne zarządzanie kartami chipowymi
GB201309971D0 (en) Oral medicines syringe
AU354914S (en) Patient interface
AU354913S (en) Patient interface
AU353572S (en) Patient interface
GB201317745D0 (en) Patient resuscitation device
TH148781B (th) สารละลายสำหรับการให้ทางช่องปาก